Financial Performance - For the interim period of the fiscal year 2023, the company recorded a revenue of approximately HKD 681.3 million, an increase of about 75.3% compared to the interim period of the fiscal year 2022[5]. - The net profit attributable to the company's owners for the interim period of the fiscal year 2023 was approximately HKD 268.1 million, a significant increase of about 196.5% from approximately HKD 90.4 million in the same period of the previous year[3]. - The company's net profit margin improved from approximately 23.3% in the interim period of the fiscal year 2022 to approximately 39.4% in the interim period of the fiscal year 2023[3]. - The company's revenue for the six months ended December 31, 2022, was HKD 681,274,000, representing a 75.3% increase from HKD 388,544,000 in the same period of 2021[90]. - Gross profit for the same period was HKD 467,840,000, up 117.5% from HKD 215,495,000 year-on-year[90]. - The company reported a profit before tax of HKD 325,092,000, compared to HKD 108,226,000 in the previous year, reflecting a 200.3% increase[90]. - Net profit for the period was HKD 268,112,000, a substantial increase of 196.5% from HKD 90,428,000 in the prior year[90]. - Basic and diluted earnings per share were HKD 70.6 cents, compared to HKD 23.8 cents in the previous year, indicating a significant improvement[90]. Operational Developments - The company has established a large health mall in Tsim Sha Tsui, expected to commence operations in the first half of 2023, to provide a one-stop medical service and health technology-related services[21]. - The company has invested in IT infrastructure and digitalization to enhance stakeholder engagement[22]. - The company has a positive outlook on the rehabilitation treatment market in Hong Kong, supported by a strategic partnership with the Chinese University of Hong Kong Hospital[10]. - The company continues to focus on providing comprehensive, one-stop, and high-quality medical services[100]. Employee and Workforce - The company employed 541 full-time employees and 1,137 part-time employees as of December 31, 2022, compared to 446 full-time and 681 part-time employees a year earlier[29]. - The total employee benefits expenses, excluding directors' remuneration, rose to HKD 70,183,000 from HKD 55,202,000, an increase of 27.2%[112]. Financial Position - As of December 31, 2022, the company's net current assets were approximately HKD 560.1 million, an increase from approximately HKD 430.8 million as of June 30, 2022[25]. - The cash and cash equivalents increased significantly to HKD 542,923,000 from HKD 270,332,000, representing a growth of 100.5%[65]. - The operating cash flow for the six months ended December 31, 2022, was HKD 455,494,000, up from HKD 283,036,000 in the previous year, indicating a year-over-year increase of 60.7%[70]. - Trade receivables decreased to HKD 291,398,000 from HKD 422,336,000, a decline of 30.9%[65]. - Current liabilities totaled HKD 328,445,000, an increase from HKD 301,094,000, representing an increase of 9.1%[65]. - The total assets less current liabilities reached HKD 1,001,347,000, up from HKD 857,520,000, indicating an increase of 16.7%[65]. Share Options and Corporate Governance - The company has not adopted any share incentive plans as of December 31, 2022[36]. - The stock options granted can be exercised from June 1, 2021, to May 31, 2027, with 34% of the options available for exercise from June 1, 2023, to May 31, 2027[38]. - The company has a total of 6,850,000 shares held by beneficial owners, representing 1.80% of the issued shares[57]. - The board has reviewed the company's corporate governance practices to ensure compliance with applicable codes[48]. - The company has complied with all applicable corporate governance code provisions during the fiscal year 2023, except for a deviation from code provision C.2.1[48]. Market Outlook and Risks - The company maintains a cautious outlook for the second half of the fiscal year 2023 due to uncertainties in the economic recovery pace and anticipated decline in demand for pandemic-related services[17].
盈健医疗(01419) - 2023 - 中期财报